MAIA Biotechnology Receives Regulatory Approval By The Spanish Agency For Medicines And Medical Devices And Portugal’s National Authority Of Medicines And Health Products To Begin Screening Patients For Its Ongoing Pivotal Phase 3 THIO-104 Clinical Trial In Non-Small Cell Lung Cancer

THIO-104 advances toward key 2027 interim survival analysis

CHICAGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer, today announced that it has received regulatory approval by the Spanish Agency for Medicines and Medical Devices (AEMPS) and Portugal’s National Authority of Medicines and Health Products (INFARMED) to begin screening patients for its ongoing pivotal Phase 3 THIO-104 clinical trial in non-small cell lung cancer (NSCLC).

Spain and Portugal represent important European markets for NSCLC, with an estimated 30,000 new cases annually across the two countries. Spain has a substantial lung cancer burden associated with historical tobacco exposure, with lung cancer incidence among women continuing to rise. In Portugal, NSCLC accounts for approximately 82% of lung cancer cases, the highest proportion reported among five European populations evaluated in a comparative study.